…
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -149.13M | -100.81M | -26.29M | -25.97M | -28.35M |
| Minority interest | 0.00M | -0.83M | -2.17M | 0.04M | 0.04M |
| Net income | -149.19M | -101.22M | -26.64M | -25.68M | -28.43M |
| Selling general administrative | 90.83M | 64.01M | 41.90M | 27.04M | 18.55M |
| Selling and marketing expenses | 30.64M | 22.15M | 17.80M | 21.36M | 17.83M |
| Gross profit | 101.02M | 65.62M | 63.47M | 49.09M | 42.94M |
| Reconciled depreciation | 4.34M | 2.85M | 3.66M | 3.64M | 2.89M |
| Ebit | -149.12M | -111.44M | -60.92M | -38.72M | -27.16M |
| Ebitda | -144.78M | -119.95M | -85.52M | -45.00M | -24.26M |
| Depreciation and amortization | 4.34M | -8.51M | -24.61M | -6.28M | 2.89M |
| Non operating income net other | - | 10.63M | 34.62M | - | - |
| Operating income | -149.12M | -111.44M | -60.92M | -38.72M | -27.97M |
| Other operating expenses | 327.77M | 249.37M | 169.01M | 124.26M | 94.61M |
| Interest expense | 0.00M | 22.82M | 65.06M | 23.77M | 0.00M |
| Tax provision | 0.06M | 0.41M | 0.34M | -0.29M | 0.08M |
| Interest income | - | 1.06M | 2.25M | 1.88M | 0.43M |
| Net interest income | - | 1.06M | 2.25M | 1.88M | 0.43M |
| Income tax expense | 0.06M | 0.41M | 0.34M | -0.29M | 0.08M |
| Total revenue | 180.96M | 137.93M | 108.09M | 85.54M | 66.64M |
| Total operating expenses | 247.84M | 177.06M | 124.39M | 87.81M | 70.91M |
| Cost of revenue | 79.93M | 72.31M | 44.62M | 36.45M | 23.70M |
| Total other income expense net | -0.00M | 10.63M | 34.62M | 12.74M | -0.81M |
| Net income from continuing ops | -149.19M | -101.22M | -26.64M | -25.68M | -28.43M |
| Net income applicable to common shares | -149.19M | -100.39M | -24.46M | -24.57M | -28.43M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 802.96M | 688.59M | 756.49M | 746.26M | 155.27M |
| Intangible assets | - | 0.59M | - | - | - |
| Other current assets | 9.93M | 26.95M | 16.84M | 8.86M | 6.97M |
| Total liab | 254.40M | 240.68M | 199.40M | 122.24M | 248.59M |
| Total stockholder equity | 548.56M | 447.89M | 557.07M | 624.01M | -93.36M |
| Deferred long term liab | - | - | 30.06M | 41.16M | - |
| Other current liab | 43.76M | 30.39M | 25.72M | 14.86M | 10.86M |
| Common stock | 0.72M | 0.71M | 0.71M | 0.70M | 0.06M |
| Capital stock | 0.72M | 0.71M | 0.71M | 0.70M | 0.06M |
| Retained earnings | -338.42M | -379.14M | -229.95M | -129.56M | -105.10M |
| Other liab | - | 26.40M | 30.36M | 41.82M | 3.10M |
| Good will | 4.79M | 4.79M | - | - | - |
| Other assets | - | 3.31M | 2.85M | 2.35M | 2.34M |
| Cash | 161.07M | 90.47M | 120.27M | 202.30M | 25.99M |
| Total current liabilities | 133.67M | 108.80M | 91.21M | 73.20M | 45.02M |
| Current deferred revenue | 56.23M | 57.93M | 55.37M | 45.40M | 25.05M |
| Net debt | -33.18M | 26.02M | -40.40M | -190.53M | -11.51M |
| Short term debt | 16.87M | 11.01M | 2.04M | 4.54M | 5.58M |
| Short long term debt total | 127.88M | 116.49M | 79.87M | 11.76M | 14.47M |
| Other stockholder equity | 885.97M | 828.70M | 786.96M | 6.29M | -179.93M |
| Property plant equipment | - | 120.23M | 10.03M | 5.14M | 19.03M |
| Total current assets | 567.80M | 533.99M | 625.06M | 682.98M | 118.54M |
| Long term investments | 83.25M | 25.68M | 43.17M | 45.66M | 15.37M |
| Net tangible assets | - | 442.52M | 557.07M | 624.01M | -93.36M |
| Short term investments | 307.69M | 360.61M | 456.21M | 440.39M | 59.84M |
| Net receivables | 89.12M | 69.09M | 40.55M | 35.38M | 25.74M |
| Inventory | - | -13.14M | -8.81M | -3.96M | - |
| Accounts payable | 16.82M | 9.47M | 8.08M | 8.40M | 3.52M |
| Noncontrolling interest in consolidated entity | - | - | 0.01M | 0.00M | - |
| Accumulated other comprehensive income | 0.28M | -2.38M | -0.65M | 0.32M | 0.02M |
| Common stock total equity | - | - | 0.71M | 0.70M | 0.06M |
| Retained earnings total equity | - | - | -229.95M | -129.56M | - |
| Non currrent assets other | 6.01M | 3.31M | 2.85M | 2.35M | 2.34M |
| Non current assets total | 235.16M | 154.60M | 131.43M | 63.28M | 36.73M |
| Capital lease obligations | 127.88M | 116.49M | 79.87M | 11.76M | 14.47M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 90.02M | -9.64M | -379.18M | -53.85M | 11.19M |
| Change to liabilities | -0.72M | 8.46M | 68.34M | 6.42M | 8.41M |
| Total cashflows from investing activities | 90.02M | -16.81M | -381.72M | -53.85M | 11.19M |
| Total cash from financing activities | 2.11M | 7.95M | 541.27M | 28.68M | 80.27M |
| Change to operating activities | 7.30M | 11.62M | 3.87M | 4.47M | -3.86M |
| Net income | -149.19M | -101.22M | -26.64M | -25.68M | -28.43M |
| Change in cash | -27.55M | -79.53M | 176.31M | -51.23M | 67.76M |
| Begin period cash flow | 123.27M | 202.80M | 26.49M | 77.72M | 9.96M |
| End period cash flow | 95.72M | 123.27M | 202.80M | 26.49M | 77.72M |
| Total cash from operating activities | -119.68M | -70.67M | 16.76M | -26.06M | -23.71M |
| Issuance of capital stock | 0.00M | 0.00M | 537.09M | 30.44M | 80.27M |
| Depreciation | 4.34M | 2.85M | 3.66M | 3.64M | 2.89M |
| Other cashflows from investing activities | - | - | - | -52.02M | 16.45M |
| Change to inventory | - | 6.44M | 7.34M | 2.91M | -3.86M |
| Change to account receivables | -23.70M | -0.32M | -12.75M | -5.04M | -4.27M |
| Sale purchase of stock | - | 7.95M | 215.67M | 30.44M | 80.27M |
| Other cashflows from financing activities | 90.02M | 7.95M | 4.18M | 28.14M | 79.38M |
| Change to netincome | 46.53M | 28.41M | 6.44M | -9.42M | 1.53M |
| Capital expenditures | 8.01M | 7.17M | 2.54M | 1.84M | 5.26M |
| Change receivables | - | -0.32M | -12.75M | - | - |
| Cash flows other operating | - | -8.84M | -22.30M | - | - |
| Cash and cash equivalents changes | - | -79.53M | 176.31M | - | - |
| Change in working capital | -21.38M | 4.68M | 59.18M | 4.29M | 0.28M |
| Stock based compensation | 39.63M | 26.49M | 10.54M | 2.19M | 1.31M |
| Other non cash items | 6.91M | 0.81M | 2.14M | 1.05M | -0.15M |
| Free cash flow | -127.70M | -77.84M | 14.22M | -27.89M | -28.97M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SDGR Schrodinger Inc |
1.58 6.16% |
27.24 | - | - | 8.83 | 3.49 | 7.28 | -9.18 |
| VEEV Veeva Systems Inc Class A |
- -% |
277.20 | 43.49 | 29.59 | 12.48 | 5.79 | 10.39 | 33.41 |
| PMCUF Pro Medicus Limited |
-5.45 3.99% |
131.10 | 64.90 | 90.91 | 49.11 | 38.05 | 65.12 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
0.19 0.30% |
63.62 | - | - | 8.68 | 25.39 | 8.33 | - |
| MTHRY M3 Inc |
-0.18 3.24% |
5.38 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Dr. Ramy Farid Ph.D. | CEO, Pres & Director | 1964 |
| Dr. Richard A. Friesner Ph.D. | Co-Founder, Scientific Advisory Chairman and Director | 1953 |
| Mr. Kenneth Patrick Lorton | Exec. VP & CTO | 1984 |
| Dr. Robert Lorne Abel Ph.D. | Exec. VP, Chief Computational Scientist and Head of Modeling R&D | 1982 |
| Dr. Karen Akinsanya Ph.D. | Pres of R&D Therapeutics | 1968 |
| Prof. William Goddard III | Co-Founder & Scientific Advisor | NA |
| Dr. Geoffrey Craig Porges MBBS | Exec. VP & CFO | NA |
| Mr. Shane Brauner | Exec. VP & Chief Information Officer | 1978 |
| Ms. Jaren Irene Madden | Sr. VP of Investor Relations & Corp. Communications | NA |
| Ms. Yvonne Tran Esq. | Exec. VP, Chief Legal Officer & Sec. | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.